A cross-border Willkie team advises Germany-based RIEMSER in its acquisition of UK-based Intrapharm.
On November 30, Willkie client RIEMSER Pharma GmbH, a German specialty pharmaceutical company, announced the acquisition of British specialty pharmaceutical company Intrapharm Laboratories Ltd. With this add-on acquisition, RIEMSER significantly strengthens its position in the UK and Northern European markets.
RIEMSER, an Ardian portfolio company, is a midsize pharmaceutical company specializing in the marketing and sophisticated life cycle management of specialty drugs for treatment of highly complex and niche disease areas.
Intrapharm is a fast-growing specialty pharmaceutical group marketing specialty pharmaceutical products with a primary focus on prescription-based and selected over-the-counter (OTC) products. Current products address therapeutic areas covering oncology, ophthalmology, pain, gastrointestinal and dermatology.
The Willkie deal team was led by partner Claire McDaid and included partners Mario Schmidt, Jan Wilms and Susanne Zuehlke; national partners Maximilian Schwab, Judith Harger and James Crooks; and associates Gerry Kelly, Antonio Laino, Martin Michalski, Wolfgang Münchow, Laura Pfirrmann, Alice Walton, Shinasa Wasimi and Henri Weil.